NYSE:RCUS

Arcus Biosciences (RCUS) Stock Price, News & Analysis

Arcus Biosciences logo
$16.18 -0.22 (-1.31%)
As of 12:22 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Arcus Biosciences Stock (NYSE:RCUS)

Advanced

Key Stats

Today's Range
$15.93
▼
$16.82
50-Day Range
$16.41
▼
$28.47
52-Week Range
$15.93
▼
$31.74
Volume
1.07 million shs
Average Volume
1.42 million shs
Market Capitalization
$2.33 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.36
Consensus Rating
Moderate Buy

Company Overview

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Founded in 2015 and headquartered in Hayward, California, the company researches therapies that target immune pathways and other processes involved in tumor growth.

Its pipeline consists of investigational medicines, including antibody and small-molecule candidates designed to be used alone or in combination. Arcus’s research has focused on areas such as checkpoint inhibition and the adenosine pathway; its candidates are under clinical development and are not established treatments.

Arcus works with Gilead Sciences on the development of oncology medicines, extending its work through a major biopharmaceutical collaboration. The company’s research and development operations are based in the United States, with its collaboration supporting development and potential commercialization across broader markets.

AI Generated. May Contain Errors.

Arcus Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

RCUS MarketRank™: 
2.907239819 of 5 stars

Arcus Biosciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 397th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 12 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Arcus Biosciences has a consensus price target of $39.36, representing about 138.8% upside from its current price of $16.49.

  • Amount of Analyst Coverage

    Arcus Biosciences has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arcus Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Arcus Biosciences are expected to grow in the coming year, from ($3.47) to ($3.10) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arcus Biosciences is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arcus Biosciences is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arcus Biosciences has a P/B Ratio of 6.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    9.90% of the float of Arcus Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Arcus Biosciences has a short interest ratio ("days to cover") of 3.56, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Arcus Biosciences has recently increased by 6.63%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Arcus Biosciences does not currently pay a dividend.

  • Dividend Growth

    Arcus Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Arcus Biosciences has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for RCUS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $84,810.00 in company stock.

  • Percentage Held by Insiders

    7.60% of the stock of Arcus Biosciences is held by insiders.

  • Percentage Held by Institutions

    92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arcus Biosciences' insider trading history.
Receive RCUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RCUS Stock News Headlines

BofA Securities Adjusts Price Target on Arcus Biosciences to $28 From $29
My $247 scanner for $7
Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.tc pixel
See More Headlines

RCUS Stock Analysis - Frequently Asked Questions

Arcus Biosciences' stock was trading at $23.90 on January 1st, 2026. Since then, RCUS shares have decreased by 31.0% and is now trading at $16.4850.

Arcus Biosciences, Inc. (NYSE:RCUS) issued its quarterly earnings data on Wednesday, November, 4th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.89) by $0.11. Arcus Biosciences's quarterly revenue was down 65.4% on a year-over-year basis.

Arcus Biosciences (RCUS) raised $112 million in an IPO on Thursday, March 15th 2018. The company issued 8,000,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Top institutional investors of Arcus Biosciences include State Street Corp (3.87%), Fisher Asset Management LLC (1.51%), Goldman Sachs Group Inc. (1.14%) and Aberdeen Group plc (0.83%). Insiders that own company stock include Gilead Sciences, Inc, Terry J Rosen, Juan C Jaen, Jennifer Jarrett, Carolyn C Tang, Robert C Goeltz II, Richard Markus, Alexander Azoy and Yasunori Kaneko.
View institutional ownership trends
.

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arcus Biosciences investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), Viking Therapeutics (VKTX) and Micron Technology (MU).

Company Calendar

Last Earnings
11/04/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NYSE:RCUS
CIK
1724521
Fax
N/A
Employees
601
Year Founded
2015

Price Target and Rating

High Price Target
$50.00
Low Price Target
$23.00
Potential Upside/Downside
+144.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$353 million
Net Margins
-453.00%
Pretax Margin
-453.00%
Return on Equity
-91.65%
Return on Assets
-46.72%

Debt

Debt-to-Equity Ratio
0.28
Current Ratio
3.34
Quick Ratio
3.34

Sales & Book Value

Annual Sales
$247 million
Price / Sales
9.39
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.49 per share
Price / Book
6.47

Miscellaneous

Outstanding Shares
143,990,000
Free Float
133,048,000
Market Cap
$2.32 billion
Optionable
Optionable
Beta
1.04

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NYSE:RCUS) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners